Novo Holdings
Novo Holdings, established in 1999, is a Danish asset management firm based in Copenhagen. It serves as the investment arm of the Novo Nordisk Foundation, managing its assets and wealth. The company's primary focus is the life science sector, with a diversified portfolio comprising equities, bonds, real estate, infrastructure, and private investments. Novo Holdings maintains a significant influence on Novo Nordisk A/S and Novozymes A/S, ensuring these companies align with the Novo Group's visions and values. It also invests in early and growth-stage life science companies through its venture capital arm, Novo Ventures, which targets investments ranging from USD 5 million to USD 30 million.
Fire1
Venture Round in 2025
Fire1, based in Dublin, Ireland, is dedicated to developing innovative therapeutic devices aimed at enhancing the lives of heart failure patients. The company has created a remote monitoring system that allows healthcare providers to access real-time patient data and insights. This technology facilitates the early detection of complications associated with heart failure, enabling proactive interventions that can lead to improved patient outcomes. Through its focus on remote monitoring, Fire1 seeks to address critical challenges in heart failure management and contribute to better healthcare solutions.
Fire1
Venture Round in 2023
Fire1, based in Dublin, Ireland, is dedicated to developing innovative therapeutic devices aimed at enhancing the lives of heart failure patients. The company has created a remote monitoring system that allows healthcare providers to access real-time patient data and insights. This technology facilitates the early detection of complications associated with heart failure, enabling proactive interventions that can lead to improved patient outcomes. Through its focus on remote monitoring, Fire1 seeks to address critical challenges in heart failure management and contribute to better healthcare solutions.
Alder Biopharmaceuticals
Series D in 2012
Alder BioPharmaceuticals is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing therapeutic antibodies to improve treatment for migraine patients in the United States, Australia, and Ireland. The company's lead candidate, eptinezumab, is a monoclonal antibody targeting calcitonin gene-related peptide, currently in late-stage clinical development for migraine prevention. Alder is also developing ALD1910, a preclinical monoclonal antibody aimed at inhibiting pituitary adenylate cyclase-activating polypeptide-38 for similar purposes, and Clazakizumab, which targets the pro-inflammatory cytokine interleukin-6 and has completed two Phase 2b trials. In addition to its product development efforts, Alder engages in strategic collaborations, notably with CSL Limited for advancing clazakizumab as a treatment for solid organ transplant rejection. Incorporated in 2002 and headquartered in Bothell, Washington, Alder operates primarily in the United States, where it generates most of its revenue.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.